APA (7th ed.) Citation

Rothenberg, M. E., Tagen, M., Chang, J. H., Boyce-Rustay, J., Friesenhahn, M., Hackos, D. H., . . . Cho, W. (2019). Safety, Tolerability, and Pharmacokinetics of GDC-0276, a Novel NaV1.7 Inhibitor, in a First-in-Human, Single- and Multiple-Dose Study in Healthy Volunteers. Clinical drug investigation, 39(9), 873-887. https://doi.org/10.1007/s40261-019-00807-3

Chicago Style (17th ed.) Citation

Rothenberg, Michael E., et al. "Safety, Tolerability, and Pharmacokinetics of GDC-0276, a Novel NaV1.7 Inhibitor, in a First-in-Human, Single- and Multiple-Dose Study in Healthy Volunteers." Clinical Drug Investigation 39, no. 9 (2019): 873-887. https://doi.org/10.1007/s40261-019-00807-3.

MLA (9th ed.) Citation

Rothenberg, Michael E., et al. "Safety, Tolerability, and Pharmacokinetics of GDC-0276, a Novel NaV1.7 Inhibitor, in a First-in-Human, Single- and Multiple-Dose Study in Healthy Volunteers." Clinical Drug Investigation, vol. 39, no. 9, 2019, pp. 873-887, https://doi.org/10.1007/s40261-019-00807-3.